Dermapharm Holding SE (DMPHF)
Dermapharm SE Statistics
Share Statistics
Dermapharm SE has 53.84M shares outstanding. The number of shares has increased by 0% in one year.
| Shares Outstanding | 53.84M |
| Shares Change (YoY) | 0% |
| Shares Change (QoQ) | 0% |
| Owned by Institutions (%) | n/a |
| Shares Floating | 13.9M |
| Failed to Deliver (FTD) Shares | - |
| FTD / Avg. Volume | < 0.01% |
Short Selling Information
| Short Interest | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Valuation Ratios
The PE ratio is 19.55 and the forward PE ratio is null. Dermapharm SE's PEG ratio is 0.24.
| PE Ratio | 19.55 |
| Forward PE | n/a |
| PS Ratio | 1.88 |
| Forward PS | n/a |
| PB Ratio | 3.68 |
| P/FCF Ratio | 13.63 |
| PEG Ratio | 0.24 |
Enterprise Valuation
Dermapharm SE has an Enterprise Value (EV) of 3.08B.
| EV / Sales | 2.61 |
| EV / EBITDA | 9.61 |
| EV / EBIT | 15.31 |
| EV / FCF | 18.89 |
Financial Position
The company has a current ratio of 1.82, with a Debt / Equity ratio of 1.62.
| Current Ratio | 1.82 |
| Quick Ratio | 0.78 |
| Debt / Equity | 1.62 |
| Debt / EBITDA | 3.05 |
| Debt / FCF | 6 |
| Interest Coverage | 3.71 |
Financial Efficiency
Return on Equity is 18.83% and Return on Invested Capital is 7.65%.
| Return on Equity | 18.83% |
| Return on Assets | 5.47% |
| Return on Invested Capital | 7.65% |
| Revenue Per Employee | $327.08K |
| Profits Per Employee | $31.52K |
| Employee Count | 3,610 |
| Asset Turnover | 0.57 |
| Inventory Turnover | 1.22 |
Taxes
| Income Tax | 60.27M |
| Effective Tax Rate | 35.04% |
Stock Price Statistics
The stock price has increased by -7.31% in the last 52 weeks. The beta is 1.33, so Dermapharm SE's price volatility has been higher than the market average.
| Beta | 1.33 |
| 52-Week Price Change | -7.31% |
| 50-Day Moving Average | 41.18 |
| 200-Day Moving Average | 42.31 |
| Relative Strength Index (RSI) | 0 |
| Average Volume (20 Days) | 1 |
Income Statement
In the last 12 months, Dermapharm SE had revenue of 1.18B and earned 113.79M in profits. Earnings per share was 2.11.
| Revenue | 1.18B |
| Gross Profit | 767.07M |
| Operating Income | 216.93M |
| Net Income | 113.79M |
| EBITDA | 320.91M |
| EBIT | 230.41M |
| Earnings Per Share (EPS) | 2.11 |
Balance Sheet
The company has 121.19M in cash and 979.61M in debt, giving a net cash position of -858.42M.
| Cash & Cash Equivalents | 121.19M |
| Total Debt | 979.61M |
| Net Cash | -858.42M |
| Retained Earnings | 433.19M |
| Total Assets | 2.08B |
| Working Capital | 266.58M |
Cash Flow
In the last 12 months, operating cash flow was 201.38M and capital expenditures -38.24M, giving a free cash flow of 163.14M.
| Operating Cash Flow | 201.38M |
| Capital Expenditures | -38.24M |
| Free Cash Flow | 163.14M |
| FCF Per Share | 3.02 |
Margins
Gross margin is 64.96%, with operating and profit margins of 18.37% and 9.64%.
| Gross Margin | 64.96% |
| Operating Margin | 18.37% |
| Pretax Margin | 14.57% |
| Profit Margin | 9.64% |
| EBITDA Margin | 27.18% |
| EBIT Margin | 18.37% |
| FCF Margin | 13.82% |
Dividends & Yields
DMPHF pays an annual dividend of $1.91, which amounts to a dividend yield of 4.82%.
| Dividend Per Share | $1.91 |
| Dividend Yield | 4.82% |
| Dividend Growth (YoY) | 7.97% |
| Payout Ratio | 79.82% |
| Earnings Yield | 5.12% |
| FCF Yield | 7.34% |
Analyst Forecast
Currently there are no analyst rating for DMPHF.
| Price Target | n/a |
| Price Target Difference | n/a |
| Analyst Consensus | n/a |
| Analyst Count | n/a |
Scores
| Altman Z-Score | 2.22 |
| Piotroski F-Score | 9 |